Edgewise Therapeutics Inc
$ 34.83
2.65%
12 Jun - close price
- Market Cap 3,747,465,000 USD
- Current Price $ 34.83
- High / Low $ 35.27 / 33.96
- Stock P/E N/A
- Book Value 4.59
- EPS -1.66
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.38 %
- 52 Week High 40.77
- 52 Week Low 12.15
About
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$46.08
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-03 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.46 | -0.47 | -0.39 | -0.34 | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 | -0.47 | -0.41 | -0.34 |
| Estimated EPS | -0.48 | -0.4359 | -0.4 | -0.42 | -0.42 | -0.4222 | -0.37 | -0.34 | -0.41 | -0.43 | -0.4 | -0.4 |
| Surprise | 0.02 | -0.0341 | 0.01 | 0.08 | -0.01 | 0.0022 | 0.01 | 0 | 0.08 | -0.04 | -0.01 | 0.06 |
| Surprise Percentage | 4.1667% | -7.8229% | 2.5% | 19.0476% | -2.381% | 0.5211% | 2.7027% | 0% | 19.5122% | -9.3023% | -2.5% | 15% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.5 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EWTX
2026-06-08 02:10:10
Edgewise Therapeutics recently announced stock option grants to new non-executive employees and received positive affirmations from Wall Street analysts, boosting its investment narrative. While this external confidence highlights upcoming clinical and regulatory milestones, the company still faces significant risks, including no revenue, substantial net losses, and a potentially high valuation. Investors should weigh these perspectives, considering the company's reliance on future financing and trial execution risks, despite analyst optimism.
2026-06-05 20:09:04
Edgewise Therapeutics (EWTX) shareholders at their Annual Meeting on June 4, 2026, elected three Class II directors—Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D.—to serve until the 2029 annual meeting. They also ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers.
2026-06-04 23:37:00
Edgewise Therapeutics (EWTX) stock remains a "Buy" following the transformative $2.65 billion sale of its muscular dystrophy program to Servier, which includes $1.55 billion in upfront cash. This cash infusion will fully fund the development of EDG-7500 for oHCM/nHCM, with a phase 3 initiation targeted for Q4 2026. Key 12-week Part D data from the phase 2 CIRRUS-HCM study for EDG-7500 is anticipated in Q2 2026, serving as a crucial catalyst for its progression.
2026-06-03 20:11:37
Edgewise Therapeutics reported inducement grants to four new employees, as permitted by Nasdaq Listing Rule 5635(c)(4). These grants, consisting of stock options to purchase 39,200 shares of common stock, were approved by the company's compensation committee and have a per share exercise price equal to the closing price on the grant date. The options vest over four years, with a 25% vesting after one year and monthly vesting thereafter, subject to continued employment.
2026-06-03 20:09:58
Edgewise Therapeutics (EWTX) has reported inducement grants, as allowed by Nasdaq Listing Rules. This news was originally sourced from Reuters and is a brief update on the company's compliance with stock exchange regulations.
2026-06-03 20:09:58
Edgewise Therapeutics announced it granted inducement stock options for 74,000 shares of common stock to four new non-executive employees on May 29, 2026. These grants, with an exercise price of $34.16 per share, are part of the company's 2024 Inducement Equity Incentive Plan and vest over four years, subject to continued employment, in accordance with Nasdaq Listing Rules. The company specializes in developing novel therapeutics for muscular dystrophies and serious cardiac conditions.
